Summary of patient cases
| Patient . | Diagnostic category . | Age, mo/Sex . | Molecular abnormality . | Induction . | Complications . | Response . |
|---|---|---|---|---|---|---|
| 1 | High-risk KMT2A-rearranged B-ALL | 1/M | KMT2A-MLLT1 | Interfant | Febrile neutropenia | Remission |
| 2 | Intermediate-risk KMT2A-rearranged B-ALL | 4/M | KMT2A-AFF1 | Interfant | Febrile neutropenia | Remission |
| 3 | Low-risk wt-KMT2A B-ALL | 10/F | None | Interfant | None | Remission |
| 4 | KMT2A-rearranged AML | 7/F | KMT2A-MLLT3 | ADE* | Gram-negative sepsis | Remission |
| 5 | wt-KMT2A megakaryoblastic AML | 4/M | RBM15-MKL1 | ADE* | Fungal pneumonia | Induction failure |
| 6 | KMT2A-rearranged MPAL (B/myeloid) | 7/F | KMT2A-MLLT10 | Interfant | Febrile neutropenia | Remission |
| Patient . | Diagnostic category . | Age, mo/Sex . | Molecular abnormality . | Induction . | Complications . | Response . |
|---|---|---|---|---|---|---|
| 1 | High-risk KMT2A-rearranged B-ALL | 1/M | KMT2A-MLLT1 | Interfant | Febrile neutropenia | Remission |
| 2 | Intermediate-risk KMT2A-rearranged B-ALL | 4/M | KMT2A-AFF1 | Interfant | Febrile neutropenia | Remission |
| 3 | Low-risk wt-KMT2A B-ALL | 10/F | None | Interfant | None | Remission |
| 4 | KMT2A-rearranged AML | 7/F | KMT2A-MLLT3 | ADE* | Gram-negative sepsis | Remission |
| 5 | wt-KMT2A megakaryoblastic AML | 4/M | RBM15-MKL1 | ADE* | Fungal pneumonia | Induction failure |
| 6 | KMT2A-rearranged MPAL (B/myeloid) | 7/F | KMT2A-MLLT10 | Interfant | Febrile neutropenia | Remission |
F, female; Interfant, Interfant induction (Figure 1); M, male; MPAL, mixed phenotype acute leukemia.
ADE indicates cytarabine 100 mg/m2 every 12 hours days 1 to 10; daunorubicin 50 mg/m2 days 1, 3, and 5; etoposide 100 mg/m2 days 1 to 5.